November 1st 2025
The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.
October 31st 2025
A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.
October 30th 2025
The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.
Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.
The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting
Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.
No Cancer Fatigue/QOL Improvement Occurs With Supervised Physical Activity
The AFSOS-Unicancer QUALIOR study did not meet its primary end point among patients with metastatic cancer.
Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor
Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.
Explicating The Valuable Role of Clinical Social Work in Oncology
Proactive disclosure of information by clinical social workers in oncology may help equip patients to handle difficult aspects of cancer treatment.
How Are Cellular Therapeutics Distributed in Global Oncology Settings?
In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.
Comprehensive Cancer Database May Enhance Personalized Therapy
Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.
Proactive Psychosocial Support May Improve Mental Health in Oncology Care
Kelly Dyckman, MSW, LCSW, discusses the need for proactive, not reactive, communication about posttreatment challenges to better support cancer survivors.
Giving Psychosocial Support for Sexual Health Issues in Cancer Care
Recommending counseling sessions may help patients with cancer navigate sexual health and emotional issues during their cancer treatment.
The Essential Role of Clinical Social Work in Oncology
Kelly Dyckman, MSW, LCSW, discusses how her role integrates with multidisciplinary oncology teams to support patients' emotional and relational well-being.
Looking Beyond Genomics to Advance Precision Medicine in Cancer Care
Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.
Exploring the Next Frontier of Cancer Biomarkers in Precision Medicine
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
Refining Artificial Intelligence Tools in Cancer Pathology and Research
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
Advancing AI in Pathology, Precision Medicine, and the Melanoma Landscape
David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.
Acknowledging Mortality and Death in Cancer Care
In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.
Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations
Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.
Episode 15: Applying ctDNA Practically to Cancer Research and Management
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.
Advancing AI in Oncology: Critical Considerations for Clinical Practice
Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.
Psycho-Social Services Can Offer Support During CAR T-Cell Therapy
Sally Werner, RN, BSN, MSHA, highlights the importance of using education, navigation programs, and caregiver support to help during CAR T-Cell Therapy treatment.
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors
An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.
How Can AI Be Safely Used to Support Patients During Cancer Treatment?
Attitudes toward the use of AI in health care were split 50/50, according to a recent survey conducted by the Cancer Support Community.
Advocating for Psychosocial Oncology Care
Sally Werner, RN, BSN, MSHA, discusses the crucial role of psychosocial oncology in cancer care, including how clinicians and administrators can advocate for these vital services.
LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors
Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.
Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types
Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.
Reducing Animal Proteins, Increasing Fiber May Benefit Patients With Cancer
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Smaller, More Frequent Meals May Mitigate Nausea in Cancer Care
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes may help stave off treatment-related nausea.
Nutritional Supplementation May Interfere With Cancer Treatment
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.